市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | PolyPid Ltd. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 1.0 |
| 平均 | 0.13 |
|
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 25.65% |
| 机构持股比例 | 49.51% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Symmetry Peak Management Llc | 30 Jun 2025 | 63,950 |
| Lumbard & Kellner, Llc | 30 Jun 2025 | 38,200 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 13.00 (HC Wainwright & Co., 263.13%) | 购买 |
| 13.00 (Craig-Hallum, 263.13%) | 购买 | |
| 中 | 13.00 (263.13%) | |
| 低 | 9.00 (Roth Capital, 151.40%) | 购买 |
| 平均值 | 11.67 (225.98%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 3.50 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Roth Capital | 13 Nov 2025 | 9.00 (151.40%) | 购买 | 3.58 |
| Craig-Hallum | 14 Aug 2025 | 13.00 (263.13%) | 购买 | 3.43 |
| HC Wainwright & Co. | 13 Aug 2025 | 13.00 (263.13%) | 购买 | 3.49 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合